Eli Lilly and Company (LLY)vsTango Therapeutics Inc (TNGX)
LLY
Eli Lilly and Company
$934.60
+3.07%
HEALTHCARE · Cap: $760.43B
TNGX
Tango Therapeutics Inc
$20.98
-2.96%
HEALTHCARE · Cap: $3.18B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 104380% more annual revenue ($65.18B vs $62.38M). LLY leads profitability with a 31.7% profit margin vs -162.9%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
TNGX
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+21.7%
Fair Value
$16.11
Current Price
$20.98
$4.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Trading at 8.2x book value
0.0% earnings growth
ROE of -37.2% — below average capital efficiency
Revenue declined 100.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : TNGX
TNGX has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : TNGX
The primary concerns for TNGX are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while TNGX is a turnaround play — different risk/reward profiles.
TNGX carries more volatility with a beta of 1.31 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 20/100), backed by strong 31.7% margins and 42.6% revenue growth. TNGX offers better value entry with a 21.7% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Tango Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tango Therapeutics Inc. is a clinical-stage biotechnology firm focused on revolutionizing cancer treatment through targeted therapies based on the principle of synthetic lethality. With a robust and diverse pipeline of innovative drug candidates, the company is poised to make significant strides in precision oncology. Tango is committed to enhancing its research capabilities through strategic partnerships with esteemed academic institutions, further solidifying its role as a leader in advancing treatment paradigms in oncology. Through its visionary approach, Tango aims to address critical unmet needs in cancer care and significantly improve patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?